Controversies in Stroke: Should Patients With Embolic Stroke of Undetermined Source Undergo Intensive Heart Rhythm Monitoring With an Implantable Loop Recorder?

Anthony S. Kim*, Hooman Kamel, Richard A. Bernstein, Monika Manchanda, Fan Z. Caprio

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)3243-3247
Number of pages5
JournalStroke
Volume53
Issue number10
DOIs
StatePublished - Oct 1 2022

Funding

Dr Kim reports grant support from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS)‚ NIH/National Institute on Minority Health and Health Disparities (NIMHD)‚ Patient-Centered Outcomes Research Institute (PCORI)‚ and American Heart Association/American Stroke Association (AHA/ASA) and is Associate Editor for NEJM Journal Watch: Neurology. Dr Kamel serves as a principal investigator for the NIH-funded ARCADIA trial (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke; NINDS U01NS095869), which receives in-kind study drug from the Bristol-Myers Squibb-Pfizer Alliance for Eliquis and ancillary study support from Roche Diagnostics; as Deputy Editor for JAMA Neurology; on clinical trial steering/executive committees for Medtronic, Janssen, and Javelin Medical; and on end point adjudication committees for NovoNordisk and Boehringer-Ingelheim. Dr Bernstein reports consulting and speakers relationships with Boehringer-Ingelheim, Pfizer, Amgen, AbbVie, Abbott, Bristol Myers, AstraZeneca, and Medtronic. The other authors report no conflicts.

Keywords

  • anticoagulation
  • atrial fibrillation
  • electrocardiography, ambulatory
  • embolic stroke
  • ischemic stroke
  • risk factors

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this